Impel NeuroPharma reports positive phase 1 trial results of INP104 to treat acute migraine headache
Nandita Vijay | February 10, 2018
Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of CNS disorders, announced positive results from a recently completed phase 1 proof-of-concept trial of INP104 for acute migraine headache. INP104 is a novel dihydroergotamine (DHE) product dosed via Impel's proprietary Precision Olfactory Delivery, or POD, intranasal delivery device.
This proof-of-concept trial, INP104-101, demonstrated statistically significant improvement in bioavailability (Cmax and AUC) of INP104 over a currently approved dihydroergotamine mesylate nasal spray, and that bioavailability of INP104 was comparable to D.H.E. 45 (dihydroergotamine mesylate) intravenous (IV) injection after twenty minutes of exposure.